Biotechnology company Dezima Pharma has secured €14.2m ($18.6m) for the development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001(previously TA-8995). The company received €9.8m capital in a Series A ...
Tags: Dezima Pharma, Biotechnology, therapies